We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $7.48B
1-Year Est. Return 104.76%
This Fund
S&P 500
This Quarter Est. Return
+10.61%
1 Year Est. Return
+104.76%
3 Year Est. Return
+313.12%
5 Year Est. Return
+388.67%
10 Year Est. Return
+3,437.54%
AUM
$1.92B
AUM Growth
+$154M
Cap. Flow
+$53M
Cap. Flow %
2.76%
Top 10 Hldgs %
26.22%
Holding
151
New
15
Increased
40
Reduced
15
Closed
11

Top Buys

Rank Stock Value
1
JELD icon
JELD-WEN Holding
JELD
+$18.8M
2
LII icon
Lennox International
LII
+$14.6M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$8.18M
4
TTD icon
Trade Desk
TTD
+$8.01M
5
VRNS icon
Varonis Systems
VRNS
+$7.91M

Top Sells

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$21.1M
2
CYBR
CyberArk
CYBR
+$14M
3
ABBV icon
AbbVie
ABBV
+$10.1M
4
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$9.2M
5
XPO icon
XPO
XPO
+$7.1M

Sector Composition

Rank Sector Weight
1 Healthcare 40.8%
2 Technology 16.87%
3 Consumer Discretionary 13.92%
4 Industrials 10.12%
5 Utilities 5.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VCYT icon
51
Veracyte
VCYT
$3.23B
$13.9M 0.73%
2,133,500
– –
TWLO icon
52
Twilio
TWLO
$37.2B
$13.6M 0.71%
575,000
+118,000
+26% +$3.31M
APTV icon
53
Aptiv
APTV
$9.08B
$13.4M 0.7%
158,000
– –
PANW icon
54
Palo Alto Networks
PANW
$307B
$13M 0.68%
540,000
+123,768
+30% +$3.01M
DOOR
55
DELISTED
MASONITE INTERNATIONAL CORP
DOOR
$12.6M 0.66%
170,000
-55,000
-24% -$3.84M
AGIO icon
56
Agios Pharmaceuticals
AGIO
$1.96B
$12.2M 0.64%
214,000
– –
NBIX icon
57
Neurocrine Biosciences
NBIX
$15.2B
$12.1M 0.63%
156,000
+31,000
+25% +$2.11M
VYGR icon
58
Voyager Therapeutics
VYGR
$190M
$11.7M 0.61%
703,425
+142,000
+25% +$2.43M
ALNY icon
59
Alnylam Pharmaceuticals
ALNY
$31.9B
$11.4M 0.6%
90,000
– –
BPMC
60
DELISTED
Blueprint Medicines
BPMC
$11.3M 0.59%
150,000
-86,000
-36% -$6.05M
ACAD icon
61
Acadia Pharmaceuticals
ACAD
$4.61B
$10.1M 0.53%
334,700
– –
TSLA icon
62
Tesla
TSLA
$1.41T
$9.34M 0.49%
450,000
– –
SRPT icon
63
Sarepta Therapeutics
SRPT
$2.19B
$8.96M 0.47%
161,000
– –
GWPH
64
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$8.38M 0.44%
63,500
– –
VIRX
65
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$8.36M 0.44%
64,727
+64,353
+17,207% +$6.03M
VRNS icon
66
Varonis Systems
VRNS
$5.45B
$8.16M 0.43%
+504,000
New +$7.91M
VBIV
67
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$7.9M 0.41%
+61,667
New +$7.58M
FENC icon
68
Fennec Pharmaceuticals
FENC
$373M
$7.39M 0.39%
+741,175
New +$7.4M
CERN
69
DELISTED
Cerner Corp
CERN
$7.29M 0.38%
108,200
– –
AKCA
70
DELISTED
Akcea Therapeutics Inc
AKCA
$7.29M 0.38%
420,000
– –
EXR icon
71
Extra Space Storage
EXR
$29B
$7.17M 0.37%
82,000
– –
BOLD
72
DELISTED
Audentes Therapeutics, Inc
BOLD
$7.03M 0.37%
225,000
– –
MYOV
73
DELISTED
Myovant Sciences Ltd.
MYOV
$6.98M 0.36%
552,100
+2,100
+0.4% +$28.2K
KALV
74
DELISTED
KalVista Pharmaceuticals
KALV
$6.91M 0.36%
709,000
+313,000
+79% +$3.26M
FPRX
75
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$6.91M 0.36%
315,000
-286,000
-48% -$9.2M
1 2
3
4 5

Similar funds

S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
CCM
Check Capital Management Costa Mesa, California $7.52B AUM 15.3% 1-Year Est. Return
O
Ossiam Paris, France $7.54B AUM 50.81% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return
HPC
HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return
FPP
Findlay Park Partners London, United Kingdom $7.41B AUM 26.32% 1-Year Est. Return
RIG
RiverFront Investment Group Richmond, Virginia $7.56B AUM 23.82% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return

Eventide Asset Management's Q4 2017 Portfolio in Review

As of Q4 2017, Eventide Asset Management held 151 positions worth $1.92B, up 8.7% from $1.76B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Eventide Asset Management's Q4 2017 filing shows 15 new, 40 increased, 15 reduced and 11 closed positions. Its largest new stake was JELD-WEN Holding: 506,500 shares worth $19.9M. The largest sale was bluebird bio, an estimated $21.1M.

By sector, the portfolio is most concentrated in Healthcare at 41% of assets, down from 42% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Eventide Asset Management's largest Q4 2017 buy was JELD-WEN Holding: 506,500 shares worth $19.9M.
  • Eventide Asset Management added most to AveXis, Inc. Common Stock in Q4 2017, an estimated $8.18M increase.
  • Eventide Asset Management's biggest Q4 2017 reduction was bluebird bio, cutting an estimated $21.1M.
  • Eventide Asset Management fully exited CyberArk in Q4 2017, selling an estimated $14M.
  • Eventide Asset Management's ten largest holdings make up 26% of its $1.92B portfolio in Q4 2017.
  • Eventide Asset Management opened 15 new positions and closed 11 in Q4 2017.
  • Eventide Asset Management's portfolio value rose 8.7% quarter-over-quarter to $1.92B.

Based on Eventide Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.